Becton Dickinson Beats Estimates, Guides Higher
Hospital buyers and medical device competitors can read steady demand in the results and the $13.10 to $13.30 full-year earnings outlook.
Updated on Nov. 5, 2026 in Corporate Finance
Becton Dickinson reported fiscal fourth-quarter profit of $696 million and revenue of $5.27 billion, both above analyst estimates. Operators in medical supply and hospital procurement should note the company's raised full-year outlook.
Why it matters
Adjusted earnings of $4.15 per share beat the Zacks analyst average of $4.06, and revenue beat the $5.12 billion estimate, signaling stronger demand for the company's medical devices than analysts expected. For businesses that buy from or compete with the manufacturer, these results indicate pricing and supply conditions remain steady.
Adjusted fourth-quarter earnings of $4.15 per share beat the Zacks analyst average of $4.06, and revenue of $5.27 billion topped the $5.12 billion estimate. Full-year revenue reached $19.46 billion, with full-year profit of $1.15 billion, or $4.09 per share.
The players
Becton Dickinson
A medical device manufacturer headquartered in Franklin Lakes, New Jersey, whose products serve hospitals, laboratories, and diagnostic providers.
The details
Becton Dickinson reported fiscal fourth-quarter results on Thursday, with GAAP profit of $696 million, or $2.54 per share. Adjusted earnings, which exclude certain items, came in higher at $4.15 per share. The company also guided full-year earnings to a range of $13.10 to $13.30 per share, a projection that frames how analysts will judge its next reporting period.
Timeline
Becton Dickinson reported fiscal fourth-quarter results on November 5, 2026.
The company expects full-year earnings in the range of $13.10 to $13.30 per share.
Market Landscape
The quarter beat the Zacks consensus on both adjusted earnings and revenue, the standard benchmark investors use for judging quarterly performance. Shares have risen 17% over the last 12 months and nearly 8% year to date, indicating the market has already priced in part of this performance.
Operators who buy medical devices should watch for any pricing or supply changes as the manufacturer reports strong results and guides full-year earnings to $13.10 to $13.30 per share. Procurement teams may use the company's raised outlook as a signal when reviewing supplier terms, though contract decisions belong with qualified counsel or an accountant.
The takeaway
Strong quarterly beats suggest steady demand for medical devices, a useful signal for procurement and competitive planning. Operators should track the company's next quarterly report against its $13.10 to $13.30 full-year guidance range.
Further reading
For broader context on how public companies report and guide earnings, explore Corporate Finance coverage.
